Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors

被引：0
|
作者：
Motzer, R. J.
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Bukowski, R. M.
Rixe, O.
Bjarnason, G. A.
Kim, S. T.
Chen, I.
Michaelson, D.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
[3] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[4] Oddzial Chemioterapii, Klin Onkol, Poznan, Poland
[5] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[6] Hosp Pitie Salpetriere, Paris, France
[7] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[8] Pfizer Inc, San Diego, CA USA
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5024
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [42] A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone
    Kollmannsberger, C. K.
    Heng, D. Y.
    Murray, N.
    Chi, K. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    Benedict, A.
    Figlin, R. A.
    Charbonneau, C.
    Kreif, N.
    Hariharan, S.
    Negrier, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    [J]. BMC Cancer, 17
  • [45] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    [J]. BMC CANCER, 2017, 17
  • [46] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    [J]. ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
  • [47] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [48] Effects of sunitinib versus interferon-alfa in health-related quality of life in patients with metastatic renal cell carcinoma (MRCC): Results from a randomized multinational phase III trial
    Cella, D.
    Li, Jz
    Cappelleri, J. C.
    Bushmakin, A.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 238 - 238
  • [49] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
  • [50] First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
    Harshman, Lauren Christine
    Kroeger, Nils
    Rha, Sun Young
    Donskov, Frede
    Wood, Lori
    Tantravahi, Srinivas Kiran
    Vaishampayan, Ulka N.
    Rini, Brian I.
    Knox, Jennifer J.
    North, Scott A.
    MacKenzie, Mary J.
    Yuasa, Takeshi
    Srinivas, Sandy
    Pal, Sumanta Kumar
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345